UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 20182019

 

OR

 

[  ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 001-38015

 

Sigma Labs, Inc.

(Exact name of registrant as specified in its charter)

 

NEVADA 27-1865814

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

3900 Paseo del Sol

Santa Fe, NM 87507

(Address of principal executive offices)

 

(505) 438-2576

(Registrant’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

(Former Name or Former Address, if Changed Since Last Report

Title of each classTrading symbolName of each exchange on which registered
Common Stock, par value $0.001 per shareSGLBThe NASDAQ Stock Market LLC

Warrants to Purchase Common Stock,

par value $0.001 per share

SGLBWThe NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No[  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer[  ]Accelerated Filer[  ]
Non-accelerated filer (do not check if a smaller reporting company)[  ]Smaller reporting company[X]
Emerging growth company[  ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes[  ]No [X]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of August 13, 2018,14, 2019, the issuer had 8,248,72913,812,590 shares of common stock outstanding.

 

 

 

 

 

SIGMA LABS, INC.

 

FORM 10-Q

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION 
  
ITEM 1. FINANCIAL STATEMENTS3
  
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS1112
  
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK1516
  
ITEM 4. CONTROLS AND PROCEDURES1516
  
PART II - OTHER INFORMATION 
  
ITEM 1. LEGAL PROCEEDINGS1617
  
ITEM 1A. RISK FACTORS1617
  
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.16
ITEM 3. DEFAULTS UPON SENIOR SECURITIES16
ITEM 4. MINE SAFETY DISCLOSURES16
ITEM 5. OTHER INFORMATION16
ITEM 6. EXHIBITS17
  
ITEM 3. DEFAULTS UPON SENIOR SECURITIES17
ITEM 4. MINE SAFETY DISCLOSURES17
ITEM 5. OTHER INFORMATION17
ITEM 6. EXHIBITS17
SIGNATURES18

2

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

Sigma Labs, Inc.

Condensed Balance Sheets

(Unaudited)

 

 June 30, 2018  December 31, 2017  June 30, 2019  December 31, 2018 
           
ASSETS                
Current Assets:                
Cash $3,519,637  $1,515,674  $696,390  $1,279,782 
Accounts Receivable, net  63,510   104,538   37,982   38,800 
Note Receivable, net  118,164   788,500 
Note Receivable  79,875   121,913 
Inventory  145,605   192,705   570,426   240,086 
Prepaid Assets  64,891   55,278   68,718   67,255 
Total Current Assets  3,911,807   2,656,695   1,453,391   1,747,836 
                
Other Assets:                
Property and Equipment, net  358,686   411,643   205,538   277,944 
Intangible Assets, net  317,161   294,396   510,718   404,978 
Investment in Joint Venture  500   500   500   500 
Prepaid Stock Compensation  130,965   31,576 
Total Other Assets  807,312   738,115   716,756   683,422 
                
TOTAL ASSETS $4,719,119  $3,394,810  $2,170,147  $2,431,258 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                
Current Liabilities:                
Accounts Payable $288,379  $100,884  $368,055  $217,488 
Dividends Payable  15,125   - 
Notes Payable  50,000   100,000   50,000   50,000 
Deferred Revenue  69,706   35,680   78,773   51,498 
Accrued Expenses  168,095   146,330   271,154   376,833 
Total Current Liabilities  591,305   382,894   767,982   695,819 
        
                
TOTAL LIABILITIES  591,305   382,894   767,982   695,819 
                
Commitments & Contingencies                
                
Stockholders’ Equity                
Preferred Stock, $0.001 par; 10,000,000 shares authorized; 350 and 0 shares issued and outstanding, respectively  -   - 
Common Stock, $0.001 par; 15,000,000 shares authorized; 8,248,729 and 4,978,929 issued and outstanding, respectively  8,249   4,979 
Preferred Stock, $0.001 par; 10,000,000 shares authorized; None issued and outstanding, respectively  -   - 
Common Stock, $0.001 par; 22,500,000 shares authorized; 10,937,590, and 8,776,629 issued and outstanding, respectively  10,938   8,777 
Additional Paid-In Capital  20,879,827   17,192,394   24,243,575   21,501,407 
Accumulated Deficit  (16,760,262)  (14,185,457)  (22,852,348)  (19,774,745)
Total Stockholders’ Equity  4,127,814   3,011,916   1,402,165   1,735,439 
                
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $4,719,119  $3,394,810  $2,170,147  $2,431,258 

 

TheSee accompanying notes are an integral part of theseto condensed financial statements.

 

3
 3

 

Sigma Labs, Inc.

Condensed Statements of Operations

(Unaudited)

 

 

Three Months Ended

June 30,

  

Six Months Ended

June 30,

  

Three Months Ended

June 30,

 

Six Months Ended

June 30,

 
 2018  2017  2018  2017  2019  2018  2019  2018 
                  
REVENUES $98,663  $290,553  $202,078  $405,076  $33,582  $98,663  $98,032  $202,078 
                                
COST OF REVENUE  68,568   111,412   142,363   185,946   60,625   68,568   157,180   142,363 
                                
GROSS PROFIT  30,095   179,141   59,715   219,130   (27,043)  30,095   (59,148)  59,715 
                                
OPERATING EXPENSES:                                
Salaries & Benefits  426,049   346,994   824,706   785,204   581,356   426,049   1,093,916   824,706 
Stock-Based Compensation  423,067   166,773   584,589   306,405   220,360   423,067   474,566   584,589 
Operating R&D Costs  95,045   131,908   217,022   186,413   118,845   95,045   264,117   217,022 
Investor & Public Relations  103,197   131,780   283,596   243,913   157,318   103,197   315,107   283,596 
Legal & Professional Service Fees  177,929   189,856   316,352   289,494   218,919   177,929   403,489   316,352 
Office Expenses  110,936   64,739   206,042   148,944   184,068   110,936   350,178   206,042 
Depreciation & Amortization  48,253   45,503   95,574   91,651   49,203   48,253   97,586   95,574 
Other Operating Expenses  38,035   30,681   71,760   62,692   38,994   38,035   77,203   71,760 
Total Operating Expenses  1,422,511   1,108,234   2,599,641   2,114,717   1,569,064   1,422,511   3,076,162   2,599,641 
                                
LOSS FROM OPERATIONS  (1,392,416)  (929,093)  (2,539,926)  (1,895,587)  (1,596,107)  (1,392,416)  (3,135,310)  (2,539,926)
                                
OTHER INCOME (EXPENSE)                                
Interest Income  3,719   12,598   17,086   12,941   7,016   3,719   12,798   17,086 
State Incentives  -   -   -   152,068   -   -   51,877   - 
Change in fair value of derivative liabilities  -   -   -   93,206 
Exchange Rate Gain  1,304   -   1,304   - 
Exchange Rate Gain (Loss)  (2,264)  1,304   (2,710)  1,304 
Interest Expense  (1,411)  (49,862)  (1,411)  (99,178)  (2,136)  (1,411)  (4,258)  (1,411)
Debt discount amortization  -   (22,382)  (36,733)  (22,382)
Loss on Disposal of Assets  -   -       (56,441)  -   -   -   (36,733)
Total Other Income (Expense)  3,612   (59,646)  (19,754)  80,214   2,616   3,612   57,707   (19,754)
                                
LOSS BEFORE PROVISION FOR INCOME TAXES  (1,388,804)  (988,741)  (2,559,680)  (1,815,373)  (1,593,491)  (1,388,804)  (3,077,603)  (2,559,680)
                                
Provision for income Taxes  -   -   -   -   -   -   -   - 
                                
Net Loss $(1,388,804) $(988,741) $(2,559,680) $(1,815,373) $(1,593,491) $(1,388,804) $(3,077,603) $(2,559,680)
                                
                                
Net Loss per Common Share – Basic and Diluted $(0.25) $(0.22) $(0.48) $(0.43) $(0.15) $(0.25) $(0.31) $(0.48)
                                
Weighted Average Number of Shares Outstanding – Basic and Diluted  5,572,015   4,570,199   5,286,362   4,207,116   10,777,590   5,572,015   10,063,806   5,286,362 

 

The

See accompanying notes are an integral part of theseto condensed financial statements.

4

Sigma Labs, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

  Six Months Ended 
  June 30, 2019  June 30, 2018 
OPERATING ACTIVITIES        
Net Loss $(3,077,603) $(2,559,680)
Adjustments to reconcile Net Loss to Net Cash used in operating activities:        
Noncash Expenses:        
Depreciation and Amortization  97,586   95,574 
Stock Based Compensation  474,150   594,915 
Loss on Write-off of Asset  -   36,733 
Change in assets and liabilities:        
Accounts Receivable  818   41,028 
Interest Receivable  27,038   38,139 
Inventory  (330,340)  47,100 
Prepaid Assets  (1,463)  (9,613)
Accounts Payable  150,567   187,495 
Deferred Revenue  27,275   34,026 
Accrued Expenses  (105,678)  21,764 
NET CASH USED IN OPERATING ACTIVITIES  (2,737,650)  (1,472,519)
         
INVESTING ACTIVITIES        
Purchase of Property and Equipment  (23,796)  (41,968)
Purchase of Intangible Assets  (107,124)  (60,147)
Payment Received from Notes Receivable  15,000   632,197 
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES  (115,920)  530,082 
         
FINANCING ACTIVITIES        
Proceeds from issuance of Series B Preferred & Warrants  -   1,000,000 
Proceeds from issuance of Series C Preferred & Warrants  -   350,000 
Gross Proceeds from issuance of Common Stock and Warrants  2,521,220   2,040,100 
Less Offering Costs  (326,890)  (443,700)
Proceeds from exercise of Warrants  75,848   - 
NET CASH PROVIDED BY FINANCING ACTIVITIES  2,270,178   2,946,400 
         
NET CHANGE IN CASH FOR PERIOD  (583,392)  2,003,963 
         
CASH AT BEGINNING OF PERIOD  1,279,782   1,515,674 
         
CASH AT END OF PERIOD $696,390  $3,519,637 
         

Supplemental Disclosures:

    
Noncash investing and financing activities disclosure:        
Conversion of Convertible Debt for Stock $-   (50,000)
Other noncash operating activities disclosure:        
Issuance of Common Stock for services $153,000  $256,264 
Disclosure of cash paid for:        
Interest $2,514  $8,761 
Income Taxes $-  $- 

See accompanying notes to condensed financial statements.

5

Sigma Labs, Inc.

Statement of Stockholders’ Equity

For the Three and Six Months Ended June 30, 2019 and 2018

(Unaudited)

  Six Months Ended 
  June 30, 2018  June 30, 2017 
OPERATING ACTIVITIES        
Net Loss $(2,559,680) $(1,815,373)
Adjustments to reconcile Net Loss to Net Cash used in operating activities:        
Noncash Expenses:        
Depreciation and Amortization  95,574   91,651 
Stock Based Compensation  594,915   307,445 
Loss on Write-off of Asset  36,733   - 
(Gain) on Change in Derivative Balance  -   (93,206)
Original Issue Discount Amortization  -   49,589 
Debt Discount Amortization  -   56,441 
Change in assets and liabilities:        
Accounts Receivable  41,028   52,769 
Interest Receivable  38,139   - 
Inventory  47,100   (40,586)
Prepaid Assets  (9,613)  (1,120)
Accounts Payable  187,495   25,430 
Deferred Revenue  34,026   35,680 
Accrued Expenses  21,764   40,220 
NET CASH USED IN OPERATING ACTIVITIES  (1,472,519)  (1,291,060)
         
INVESTING ACTIVITIES        
Purchase of Property and Equipment  (41,968)  (11,380)
Purchase of Intangible Assets  (60,147)  (22,054)
Advance of Funds for Note Receivable  -   (762,034)
Proceeds from Note Receivable  632,197   - 
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES  530,082   (795,468)
         
FINANCING ACTIVITIES        
Proceeds from issuance of Series B Convertible Preferred & Warrants  1,000,000   - 
Proceeds from issuance of Series C Convertible Preferred & Warrants  350,000   - 
Gross Proceeds from issuance of Common Stock and Warrants  2,040,100   5,823,300 
Offering Costs Paid  (443,700)  (750,664)
NET CASH PROVIDED BY FINANCING ACTIVITIES  2,946,400   5,072,636 
         
NET CHANGE IN CASH FOR PERIOD  2,003,963   2,986,108 
         
CASH AT BEGINNING OF PERIOD  1,515,674   398,391 
         
CASH AT END OF PERIOD $3,519,637  $3,384,499 
         
Supplemental Disclosures:        
Noncash investing & financing activities disclosure:        
Conversion of Convertible Debt for Stock $(50,000) $- 
Other noncash operating activities disclosure:        
Issuance of Common Stock for services $252,264  $51,408 
Disclosure of cash paid for:        
Interest $8,761  $50,418 
Income Taxes $-  $- 
   Common Stock         
   Shares Outstanding    Common Stock   AdditionalPaid-in Capital   Accumulated Deficit   Total   
Balances, January 1, 2019  8,776,629  $8,777  $21,501,407  $(19,774,745) $1,735,439 
                     
Net Loss  -   -   -   (1,484,112)  (1,484,112)
Shares sold in Public Offering  1,400,800   1,401   1,677,930   -   1,679,330 
Shares issued for Exercise of Warrants  70,230   70   75,778   -   75,848 
Shares Issued for Cashless Exchange of Unit Purchase Options  88,431   88   (88)  -   - 
Shares Issued for Services  201,500   202   77,798   -   78,000 
Stock Options Awarded to Employees  -   -   176,206   -   176,206 
Balances, March 31, 2019  10,537,590  $10,538  $23,509,031  $(21,258,857) $2,260,711 
 Net Loss  -   -   -   (1,593,491)  (1,593,491)
Shares sold in Private Placement  400,000   400   514,600   -   515,000 
Shares Issued for Services  -   -   75,000   -   75,000 
Stock Options Awarded to Employees  -   -   144,944   -   144,944 
                     
Balances, June 30, 2019  10,937,590   10,938   24,243,575   (22,852,348)  1,402,165 

 

  Common Stock       
  Shares Outstanding  Common Stock  Additional
Paid-in
Capital
  Accumulated Deficit  Total 
Balances, January 1, 2018  4,978,929  $4,979  $17,192,394  $(14,185,457) $3,011,916 
                     
Net Loss  -   -   -   (1,170,876)  (1,170,876)
Shares Issued for Services  23,256   23   39,977   -   40,000 
Stock Options Awarded to Employees  -   -   140,305   -   140,305 
                     
Balances, March 31, 2018  5,002,185  $5,002  $17,372,676  $(15,356,333) $2,021,345 
Net Loss  -   -   -   (1,388,804)  (1,388,804)
Shares Issued for Services  176,744   177   216,087       216,264 
Convertible Preferred Shares Issued in Private Placement  -   -   877,499   -   877,499 
Shares Issued for Conversion of Series B Preferred  1,000,000   1,000   (1,000)  -   - 
Preferred Dividends Due Upon Conversion  -   -   -   (15,125)  (15,125)
Shares Issued for Notes Payable Conversions  25,000   25   49,975   -   50,000 
Shares Issued for Cashless Exchange of Warrants  4,800   5   (5)  -   - 
                     
Shares Sold in Public Offering  2,040,000   2,040   1,720,360   -   1,722,400 
Series C Convertible Preferred Shares Issued  -   -   346,500   -   346,500 
Stock Options Awarded to Employees  -   -   297,735   -   297,735 
                     
Balances, June 30, 2018  8,248,729   8,249   20,879,827   (16,760,262)  4,127,814 

The

See accompanying notes are an integral part of theseto condensed financial statements.

6

SIGMA LABS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

June 30, 20182019

(Unaudited)

 

NOTE 1 - Summary of Significant Accounting Policies

 

Nature of Business -Sigma Labs, Inc., formerly named Framewaves, Inc., a Nevada corporation, was founded by a group of scientists, engineers and businessmen to develop and commercialize novel and unique manufacturing and materials technologies. Sigma believes that some of these technologies will fundamentally redefine conventional quality assurance and process control practices by embedding them into the manufacturing processes in real time, enabling process intervention and ultimately leading to closed loop process control. The Company anticipates that its core technologies will allow its clientele to combine advanced manufacturing quality assurance and process control protocols with novel materials to achieve breakthrough product potential in many industries including aerospace, defense, oil and gas, bio-medical, and power generation. The terms the “Company,” “Sigma,” “we,” “us” and “our” refer to Sigma Labs, Inc.

 

Basis of Presentation - The accompanying financial statements have been prepared by the Company in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim reporting.America. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at June 30, 20182019 and 20172018 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. The Company suggests these condensed financial statements be read in conjunction with the December 31, 20172018 audited financial statements and notes thereto included in the Company’s Form 10-K. The results of operations for the periods ended June 30, 20182019 and 20172018 are not necessarily indicative of the operating results for the full year.

 

Reclassification- Certain amounts in prior-period financial statements have been reclassified for comparative purposes to conform to presentation in the current-period financial statements. In addition, $153,013 of issuance costs associated with the February 2017 capital raise have been reclassified from operating costs to a reduction in additional paid in capital.

Continuing Operations - The Company has sustained losses and had negative cash flows from operating activities since its inception. In 2017 and the first six months of 2018, management has reported a change of strategy under which the company ceased to make sales and installations for research and development applications in order to focus its efforts entirely on potential customers already manufacturing 3D metal parts and therefore, already in need of quality improvement. The result of this change between September 2017 and the second quarter of 2018 was a significant decrease in revenues which the Company hopes to replace with orders for serial production use. The Company has raised significant equity capital as it continues to develop new products with commercial applications that may increase future revenues. On February 21, 2017, the Company closed an underwritten public offering of equity securities resulting in net proceeds of approximately $5,097,000, after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company was able to fund operations for 2017 with these funds and end the year with a cash balance of $1,515,674. On March 28, 2018, Sigma received $535,000 in full payment of the Morf 3D note and related accrued interest balance. In addition, on April 6, 2018, the Company closed a private placement offering of equity securities resulting in net proceeds of approximately $877,500, after deducting commissions and other offering expenses payable by the Company. On June 26, 2018 the Company closed a public offering of equity securities resulting in net proceeds of approximately $2,068,900, after deducting placement agent commissions and other offering expenses payable by the Company. As a result, the Company currently has sufficient cash and working capital to fund operations through the first quarter of 2019 and is anticipating that sales contracts may be closed in the second half of fiscal 2018 generating additional cash flow in the near term.

 

Loss Per Share -The computation of loss per share is based on the weighted average number of shares outstanding during the period in accordance with ASCAccounting Standards Codification (“ASC”) Topic No. 260, “Earnings Per Share.” Shares underlying the CompaniesCompany’s outstanding warrants, options or note conversion features were excluded due to the anti-dilutive effect they would have on the computation. At June 30, 2019 the Company had 3,620,610 warrants, 1,108,192 stock options and a $50,000 Convertible Note Payable outstanding. The total number of shares of common stock underlying these instruments is 4,753,802. At June 30, 2018 the Company had 350 convertible preferred stock shares, 3,477,0603,228,500 warrants, 664,707 stock options and a $50,000 Convertible Note Payable outstanding. The total number of shares of common stock underlying these instruments is 4,516,767. At June 30, 2017 the Company had 1,701,500 warrants, 229,938 stock options and $1,000,000 in Convertible Notes Payable outstanding. The total number of shares of common stock underlying these instruments was 2,431,438.4,268,207.

7

 

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended June 30, 20182019 and 2017:2018:

 

 Three Months Ended June 30 Six Months Ended June 30  Three Months Ended June 30 Six Months Ended June 30 
 2018 2017 2018 2017  2019 2018 2019 2018 
                  
Net Loss per Common Share - Basic and Diluted $(0.25) $(0.22)  (0.48) $(0.43) $(0.15) $(0.25)  (0.31) $(0.48)
Loss from continuing                                
Operations available to                
Common stockholders (numerator) $(1,388,804) $(988,741)  (2,559,680) $(1,815,373)
Operations available to Common stockholders (numerator) $(1,593,491) $(1,388,804)  (3,077,603) $(2,559,680)
                                
Weighted average number of common shares Outstanding used in loss per share during the Period (denominator)  5,572,015   4,570,199   5,286,362   4,207,116   10,777,590   5,572,015   10,063,806   5,286,362 

Recently Enacted Accounting Standards - The FASB established the Accounting Standards Codification (“Codification” or “ASC”)ASC as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”).GAAP. Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) issued under authority of federal securities laws are also sources of GAAP for SEC registrants.

 

Recent Accounting Standards Updates (“ASU”) throughIn February 2016, the FASB issued ASU No. 2018-11 contain technical corrections2016-02, “Leases” which was issued to existing guidance or affects guidance to specialized industries or situations.increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company has evaluated recently issued technical pronouncementsthis standard and has determined that other than ASU 2014-09 (Topic 606), addressed below, these updates have no current applicability to the Company or their effect on the financial statements wouldit will not have been significant.

In May 2014, the FASB issued ASU 2014-09 (Topic 606) “Revenue from Contracts with Customers.” Topic 606 supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition” (Topic 605), and requires entities to recognize revenue when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. On January 1, 2018, we adopted Topic 606 and all related amendments (“new revenue standard”) to those contracts which were not completed as of January 1, 2018 using the modified retrospective method. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. There is nocurrently require any adjustment to the opening balance of retained earnings due to the cumulative effect of initially applying the new revenue standard determined to be immaterial. We expect the impact of the adoption of the new revenue standard to be immaterial to our net income on an ongoing basis.Sigma’s financial reporting.

 

Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated by management. Significant accounting estimates that may materially change in the near future are impairment of long-lived assets, values of stock compensation awards and stock equivalents granted as offering costs, and allowance for bad debts and inventory obsolescence.

 

NOTE 2 - Notes Receivable

 

On May 1, 2017, the Company made a loan in the principal amount of $250,000 to Jaguar Precision Machine, LLC, a New Mexico limited liability company (“Jaguar”), pursuant to a Secured Convertible Promissory Note dated May 1, 2017 delivered by Jaguar to the Company. The loan borebears interest at the rate of 7% per annum, was originally due and payable in full on MayAugust 1, 2018, wasis secured by certain assets of Jaguar, and is convertible at the Company’s option into 10% of the outstanding shares of the common stock of Jaguar unless Jaguar exercises its right under specified circumstances to repay all principal and accrued interest on the loan. The purpose of the loan was to provide working capital to Jaguar to, among other things, stand up a metallurgical laboratory and become ASM9100 certified for contracts related to AM of high-precision aerospace and defense components, in furtherance of our strategic alliance. Sigma received from Jaguar priority for use of certain machines and services of Jaguar. On April 27, 2018, the promissory note was amended whereby the due date of the note was extended to June 1, 2018 in exchange for a cash payment of $5,000 received on May 1, 2018, 50% of which will be retained as payment for the 30-day extension. On June 6, 2018 the promissory note was amended whereby the due date was extended to August 1, 2018 in exchange for cash payments of $10,000 by each of June 7, 2018 and July 1, 2018, $8,000 of which is to be retained as payment for the 60-day extension. The first of the $10,000 payments was received by the Company on June 6, 2018. On June 15, 2018, the Company received a $150,000 payment from Jaguar, $17,803 of which was applied to accumulated interest through that date and $132,197, the balance, of which, was applied to the principal balance of the note. This resulted in aIn the first six months of 2019 payments totaling $45,000 were received. The payments were applied first to the accumulated interest balance on the note and then to the remaining principal balance. The holder of the promissory note has committed to paying the remaining principal balance along with accumulated interest on or before September 30, 2019. The June 30, 20182019 principal balance of $117,803the note was $79,875 and the accumulated interest of $361balance due on the note.

On March 27, 2017, the Company made a loan in the principal amount of $500,000 bearing interest at the rate of 7% per annum to Morf3D, Inc., an Illinois corporation, pursuant to a Secured Convertible Promissory Note dated March 27, 2017 delivered by Morf3D to the Company. The $500,000 loan principal and $35,000 of accumulated interest was paid in full on March 27, 2018.$166.

 

NOTE 3 - Inventory

 

At June 30, 20182019 and December 31, 2017,2018, the Company’s inventory was comprised of:

 

 June 30, 2018  December 31, 2017  June 30, 2019  December 31, 2018 
Raw Goods $125,614  $127,076 
Raw Materials $279,835  $168,623 
Work in Process  -   251   265,816   46,688 
Finished Goods  19,991   65,378   24,775   24,775 
Total Inventory $145,605  $192,705  $570,426  $240,086 

NOTE 4 - Notes Payable

 

At June 30, 20182019 the Company had a $50,000 convertible note bearing interest at a rate of 10% per annum outstanding which is due on October 18, 2018.2019. At June 30, 2019 the accumulated interest balance on the note was $1,028.

8

 

NOTE 5 - Stockholders’ Equity

 

Common Stock

Effective March 5, 2018, the Articles of Incorporation were amended to increase the authorized number of shares of common stock to 15,000,000.

In 2017, the Company issued 40,934 shares of common stock to directors at an average value of $2.09 per share, or $85,408. Also in 2017, 7,750 shares previously issued to a director and 750 shares previously issued to an employee, with a combined carrying value of $9,830, were forfeited.

Ronald Fisher, the Company’s Vice President of Business Development, continues to be entitled to receive performance-based stock and cash bonuses under his Employment Offer Letter Agreement if certain milestones are satisfied by December 31, 2018, so long as Mr. Fisher remains an employee of the Company as of the date the applicable milestone is satisfied.

 

In January 2018, the Company issued 23,256 shares of common stock to directors valued at $1.72 per share, or $40,000.

 

In April 2018, the Company issued 176,744 shares of common stock to directors valued at $1.2236$1.22 per share, or $216,264.

 

Between May 29, 2018 and June 1, 2018, we issued an aggregate of 1,000,000 shares of common stock upon conversion of the 1,000 shares of Series B Preferred Stock issued on April 6, 2018 (as described below under “Preferred Stock”).

 

In May 2018 the holder of our Note Payable converted $50,000 of the principal balance of the Note into 25,000 shares of common stock and exercised its warrant on a cashless basis resulting in the issuance of 4,800 shares of common stock.

On June 26, 2018, as part of its public offering of equity securities, described in Note 1, the Company issued 2,040,000 shares of common stock and warrants to purchase a total of 717,000 shares of common stock (including the warrants described under “Preferred Stock” below that were issued on June 26, 2018). Each warrant has an initial exercise price of $1.08 per share. The net proceeds to the companyCompany were approximately $2,068,900 after commissions and other offering expenses. The Company also issued Dawson James Securities, Inc., its placement agent in the public offering, a Unit Purchase Option to acquire up to 191,200 Units, at an exercise price of $1.25 per Unit, consisting of 191,200 shares of common stock and warrants to purchase up to 57,360 shares of common stock as compensation.

 

In January 2019, the Company issued a total of 200,000 shares of common stock to directors valued at $1.50 per share, or $300,000, with such shares to vest ratably over four quarterly installments, subject in each case to such director’s continuing service as a director.

Also in January 2019, the Company issued 88,431 shares of common stock upon the cashless exercise of Unit Purchase Options issued in our June 2018 public offering.

In January and February 2019, the Company issued a total of 70,230 shares of common stock upon the exercise of 70,230 warrants having an exercise price of $1.08 resulting in gross cash proceeds of $75,848.

In March 2019, the Company issued 1,500 shares of common stock to the Company’s Vice President of Business Development in connection with his achievement of performance milestones, with such shares vesting immediately.

Also in March 2019, the Company closed a public offering of equity securities in which it issued 1,400,800 shares of common stock and warrants to purchase a total of 420,240 shares of common stock resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by the Company.

In May 2019, the Company closed a private placement of equity securities in which it issued 400,000 shares of common stock and warrants to purchase a total of 220,000 shares of common stock resulting in net proceeds of approximately $515,000, after deducting placement agent commissions and other offering expenses payable by the Company.

Deferred Compensation

 

In previous years and in the six months ended June 30, 2018,2019, the Company issued to various employees, directors, and contractors shares of the Company’s common stock, subject to restrictions, pursuant to the 2013 Equity Incentive Plan (the “2013 Plan”). Such shares were valued at the fair value at the date of issue. The fair value was expensed as compensation over the vesting period and recorded as a reduction ofan increase to stockholders’ equity. During the six months ended June 30, 20182019 and June 30, 2017,2018, $153,000 and $156,875, and $106,806, respectively, of the unvested compensation cost related to these issues was recognized.

 

As ofAt June 30, 2018 and December 31, 2017, the balance2019, there was $150,000 of unvestedunrecognized deferred compensation expense to be recognized was $130,965 and $31,576, respectively and is recorded as prepaid stock compensation asover the remainder of those dates.the year.

 

Preferred Stock

9

 

The Company is authorized to issue 10,000,000 shares of preferred stock, $0.001 par value. 350 and 0 shares of preferred stock were issued and outstanding at June 30, 2018 and December 31, 2017, respectively.

On April 6, 2018, Sigma issued 1,000 shares of the Company’s newly-created non-voting Series B Convertible Preferred Stock, which were convertible into 1,000,000 shares of common stock and warrants to purchase an aggregate of 750,000 shares of the Company’s common stock, for an aggregate purchase price of $1,000,000. The warrants have an initial exercise price of $1.47 per share, the closing price of the Company’s Common Stock reported on The NASDAQ Capital Market on April 6, 2018, subject to adjustment in certain circumstances. The net proceeds to the company were approximately $877,500 after commissions and other offering expenses. Sigma also issued Dawson James Securities, Inc., its placement agent in the foregoing private placement, warrants to purchase up to 140,000 shares of common stock, at an exercise price of $1.47 per share, as compensation

On June 26, 2018, as part of the public offering described in Note 1, the Company issued 350 of the Company’s newly-created non-voting Series C Convertible Preferred Stock, which were convertible into 350,000 shares of common stock, and warrants to purchase an aggregate of 105,000 shares of the Company’s common stock. The warrants have an initial exercise price of $1.08 per share, 11% above the closing price of the Company’s Common Stock reported on The NASDAQ Capital Market on June 26, 2018, subject to adjustment in certain circumstances.

 

Stock Options

 

In October 2018, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 900,000 shares of our common stock to a total of 1,650,000 shares. As of June 30, 2018,2019, an aggregate of 750 shares and 664,70725,460 shares of common stock were reserved for issuance under the 2011 Plan and the 2013 Plans,Plan, respectively.

 

On February 21, 2018,During the six months ended June 30, 2019, the Company granted Mark Cola, an officer of the company, ten-year options under the 2013 Plan to purchase an aggregatea total of 123,500286,925 shares of common stock with the options having an exercise price of $1.49 per share, to vest18 employees and become exercisable ratably over 17 monthly installments on the 15th day of each month commencing on March 15, 2018, subject in each case to Mr. Cola’s continuing employment.

On February 26, 2018, the Company granted nine employees ten-year options under the 2013 Equity Incentive Plan to purchase an aggregate of 70,188 shares of common stock, with each option having an exercise price of $1.56 per share, and1 consultant with vesting periods ranging from 3immediately upon issuance to 4 years beginning February 26,January 2019.

On April 19, 2018, Sigma granted John Rice, our Chief Executive Officer, three options to purchase up to 20,000 shares of our common stock under our 2013 Plan. In addition, on each of April 30, May 31, and June 30, 2018, Sigma granted Mr. Rice an option to purchase up to 20,000 shares of our common stock under our 2013 Plan. The foregoing options have an exercise price per share equal to $1.88, $1.54, $1.48, $1.26, $1.47, and $1.19 respectively, which is at least the closing price of our common stock on the respective date of grant, and each is fully vested as of the respective grant date.

The Company also agreed to grant Mr. Rice an option to purchase up to 20,000 shares on July 31, 2018, so long as Mr. Rice remains an employee of the Company as of that date (except that if Mr. Rice ceases to be employed by the Company as a result of a disability, the Option will still be granted on the applicable grant date) with an exercise price equal to the greater of (x) the average closing price of our common stock during the applicable month, and (y) the closing price of our common stock on the date of grant, and will be vested in full on the date of grant.

On April 19, 2018, Sigma granted Ron Fisher, our Vice President of Business Development, a five-year option to purchase an aggregate of 28,750 shares of common stock, with such option having an exercise price of $1.22 per share, and vesting in four annual installments over four years following the date of grant (1,366 shares, 4,097 shares, 6,828 shares and 15,021 shares, respectively)

 

During the six months ended June 30, 2018, the Company granted options to purchase 178,813a total of 374,769 shares of common stock vested,to 15 employees and $438,040 of compensation cost was recognized. As of June 30, 2018, there were options1 consultant with vesting periods ranging from immediately upon issuance to purchase 664,707 shares issued and outstanding under the 2013 Plan. Of this amount, there are vested options exercisable for 295,318 shares of common stock. No options were exercised during the six months or the quarter ended June 30,4 years beginning March 2018.

 

The Company generally grants stock options to employees and directors at exercise prices equal to the fair market value of the Company’s stock on the dates of grant. Stock options are typically granted throughout the year and generally vest over four years of service and expire tenfive years from the date of the award, unless otherwise specified. The Company recognizes compensation expense for the fair value of the stock options over the requisite service period for each stock option award.

 

Total share-based compensation expense included in the condensedconsolidated statements of operations for the six months ended June 30, 2019 and 2018 is $474,566 and 2017 is $584,589 and $306,405, of which $438,040$321,149 and $199,545$438,039 is related to stock options, respectively. There was no capitalized share-based compensation cost as of June 30, 2018 and 2017.

 

The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the six months ended June 30, 20182019 and 2017:2018:

 

  2018  2017 
Dividend yield  0.00   0.00 
Risk-free interest rate  2.68-2.97%  2.21-2.45%
Expected volatility  116.3-137.3%  137.8-139.0%
Expected life (in years)  5-10   10 

Assumptions:

  2019  2018 
Dividend yield  0.00   0.00 
Risk-free interest rate  1.90-2.54%  2.68-2.97%
Expected volatility  105.2-106.1%  116.3-137.33%
Expected life (in years)  5   5-10 

10

Option activity for the six months ended June 30, 2019 and the year ended December 31, 2018 was as follows:

     Weighted Average  Weighted Average    
     Exercise  Remaining  Aggregate 
     Price  Contractual  Intrinsic 
  Options  ($)  Life (Yrs.)  Value ($) 
Options outstanding at December 31, 2017  299,938   4.40   7.33    
Granted  534,329   1.45   6.58    
Exercised  -   -   -    
Forfeited or cancelled  (8,000)  4.59   -    
Options outstanding at December 31, 2018  826,267   2.49   6.47    
Granted  286,925   1.55   4.63    
Exercised  -   -   -    
Forfeited or cancelled  (5,000)  1.15   -    
Options outstanding June 30, 2019  1,108,192   2.25   5.61   45,830 
Options expected to vest in the future as of June 30, 2019  388,858   2.22   5.48   28,309 
Options exercisable at June 30, 2019  719,334   2.28   5.69   17,521 
Options vested, exercisable, and options expected to vest at June 30, 2019  1,108,192   2.25   5.61   45,830 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price currently below the $1.40 closing price of our common stock on June 30, 2019. 22,916 of the 2019 option grants have an exercise price currently below $1.40.

At June 30, 2019, there was $348,220 of unrecognized share-based compensation expense related to unvested share options with a weighted average remaining recognition period of 3.02 years.

 

Warrants

 

AtWarrant activity for the six months ended June 30, 2019 and 2018 the Company had outstanding warrants to purchase a total of 3,477,060 shares of common stock; 1,621,500 warrants at an exercise price of $4.00 per share, which if not exercised, will expire on February 21, 2022, 890,000 warrants at an exercise price of $1.47 per share, which if not exercised, will expire on June 26, 2023, 717,000 warrants at an exercise price of $1.08 per share, which if not exercised, will expire on June 26, 2023, and 248,560 warrants at an exercise price of $1.25, which if not exercised, will expire on June 26, 2023.was as follows:

 

On May 31, 2018, 24,000 warrants with an exercise price of $2.00 were exercised in a cashless exchange transaction resulting in the issuance of 4,800 shares of the Company’s common stock.

     Weighted Average  Weighted Average 
     Exercise  Remaining 
     Price  Contractual 
  Warrants  ($)  Life (Yrs.) 
Warrants outstanding at December 31, 2017  1,645,500   3.97   4.11 
Granted  1,607,000   1.30   4.64 
Exercised  (24,000)  2.00   - 
Forfeited or cancelled  -   -   - 
Options outstanding at June 30, 2018  3,228,500   2.65   4.40 
             
Options outstanding at December 31, 2018  3,050,600   2.75   3.86 
Granted  640,240   1.60   4.94 
Exercised  (70,230)  1.08   - 
Forfeited or cancelled  -   -   - 
Options outstanding at June 30, 2019  3,620,610   2.58   3.63 

 

NOTE 6 - Subsequent Events

 

OnIn July and August 1, 2018,of 2019, the Company increased the annual base salarygranted our CEO and President two options to purchase up to 22,916 and 22,922 shares of John Rice, the Company’s Chief Executive Officer, from $108,000 to $155,000. The Company also agreed to grant Mr. Rice an optionour common stock, respectively under the Company’sour 2013 Equity Incentive Plan (the “Plan”) onin connection with his employment arrangement. The options have an exercise price per share equal to $1.40 and $0.74, respectively, and each is fully vested.

In July of November 1, 2018, February 1, 2019, May 1, 2019 and August 1, 2019at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to purchase 68,750the 2013 Equity Incentive Plan to increase the number of shares of the Company’s common stock so long as Mr. Rice is an employeereserved for issuance under the 2013 Plan by 750,000 shares of our common stock to a total of 2,400,000 shares.

In July of 2019, the Company on each applicable grant date. Each option will have an exercise price equalgranted options to the closing pricepurchase a total of the Company’s common stock on the grant date, will have a term of five years, will be fully vested on the grant date and will have the other terms set forth in the Company’s standard-form non-qualified option agreement. Each option is subject to the approval of the Company’s stockholders at the next annual meeting of stockholders of a proposed increase in the aggregate number of97,500 shares of common stock that are issuable underto 7 employees and 1 consultant with vesting periods ranging from immediately upon issuance to 4 years beginning July 2020.

In August of 2019, the Plan.Company closed a public offering of equity securities in which it issued 2,875,000 shares of common stock resulting in net proceeds of approximately $1,971,000, after deducting placement agent commissions and other offering expenses payable by the Company.

11

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward-looking statements

 

This Quarterly Report, including any documents which may be incorporated by reference into this Report, contains “Forward-Looking Statements.” All statements other than statements of historical fact are “Forward-Looking Statements” for purposes of these provisions, including any projections of revenue or other financial items, any statements of the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All Forward-Looking Statements included in this document are made as of the date hereof and are based on information available to us as of such date. We assume no obligation to update any Forward-Looking Statement. In some cases, Forward-Looking Statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “potential,” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the Forward-Looking Statements contained herein are reasonable, there can be no assurance that such expectations or any of the Forward-Looking Statements will prove to be correct, and actual results could differ materially from those projected or assumed in the Forward-Looking Statements. Future financial condition and results of operations, as well as any Forward-Looking Statements are subject to inherent risks and uncertainties, including any other factors referred to in our press releases and reports filed with the Securities and Exchange Commission (“SEC”). All subsequent Forward-Looking Statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Additional factors that may have a direct bearing on our operating results are described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 20172018 and elsewhere in this report.

 

Corporation Information

 

Our principal executive offices are located at 3900 Paseo del Sol, Santa Fe, New Mexico 87507, and our telephone number is (505) 438-2576. Our website address iswww.sigmalabsinc.com. The Company’s annual reports, quarterly reports, current reports on Form 8-K and amendments to such reports filed or furnished pursuant to sectionSection 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), and other information related to the Company, are available, free of charge, on that website as soon as we electronically file those documents with, or otherwise furnish them to, the SEC. The Company’s website and the information contained therein, or connected thereto, are not and are not intended to be incorporated into this Quarterly Report on Form 10-Q.

 

20182019 Developments

 

In the second quarter of 2018,2019, we reported several events, including the following (in reverse chronological order):

On June 26, 2018August 13, 2019, we announced that we have been selected by a major international OEM machine manufacturer to install our proprietary PrintRite3D® products. As part of the Companyagreement, the OEM will complete our Rapid Test and Evaluation program and will install the PrintRite3D® in two different countries for analysis and proof-of-performance purposes.

On August 2, 2019, we closed a public offering of equity securities in which we issued 2,875,000 shares of its common and preferred stock and warrants to purchase common stock resulting in net proceeds of approximately $2,068,900.$1,971,000, after deducting placement agent commissions and other offering expenses payable by us.

 

On July 30, 2019, we announced that we will work with Airbus to complete a Test and Evaluation Program of our new PrintRite3D® version 5.0 hardware and software followed by a validation phase on a powderbed fusion printer.

On June 19, 2018, Sigma received notice18, 2019, we announced that its U.S. Patent No. 9999924 entitled “Method and Systemwe signed a non-binding Memorandum of Understanding with Materialise NV to cooperate in the integration of their MCP Controller with our PrintRite3D® technology. Combining the sophisticated control technology with in-situ process monitoring for Monitoringmetal additive manufacturing will give customers maximal control on the production process, allowing them to become even more productive.

On May 14, 2019, we announced that we will launch Version 5.0 of our PrintRite3D® platform at the RAPID+TCT 2019 Additive Manufacturing Processes” had been issued. The patent provides protection for methods of assuring part quality using real time data from multiple sensor types. The patent enables serial production applications through real time tracking and reporting of process consistency and part repeatability. The patent being issued is for the first application filedConference in a series of 18 patent applications submitted by Sigma over these past 5 years in the general domain of in process quality assurance.Detroit on May 21-23, 2019.

 

On MayApril 30, 2018,2019, we announced that the CompanyCompany’s PrintRite3D® software has developedbeen shown to ensure process consistency and demonstrated closed-loop feedback controlproduct quality in metal additive manufacturing, according to a research study sponsored by the Defense Advanced Research Project Agency (DARPA) Open Manufacturing Program and conducted in tandem with Honeywell Aerospace at Honeywell’s Advanced Manufacturing Engineering Center. The paper, titled “LPBF [Laser Powder Bed Fusion] Right the First Time-the Right Mix Between Modeling and Experiments,” discusses the validation involved in manufacturing a challenging metal component.

12

On March 26, 2019, we announced the appointment of the metal laser powder bed fusion 3D printing process. Using Sigma’s PrintRite3D® technology,Company’s new Business Development Manager, Americas, who will be responsible for developing key accounts through the system operates by monitoring the process outputCompany’s Rapid Test and extracting process metrics. The process metrics are then compared to baseline metrics. The system then determines what process input parameter values need to be changedEvaluation Program and implements those remedial changesfor bringing PrintRite3D INSPECT® into deployment across serial production operations in real time by signaling a change in the laser power in order to maintain the process under control.North and South America.

 

On May 21, 2018,March 15, 2019, we receivedclosed a letter from Nasdaq notifying the Companypublic offering of equity securities resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by us.

On February 26, 2019, we announced that we were named a member of the Manufacturing Technology Centre (“MTC”) located at Ansty Park, Coventry, UK. Being a member of the MTC enables us to share and provide expertise and solutions for a number of MTC’s projects and also network with MTC’s existing members, including some of the UK’s leading aerospace companies.

On February 12, 2019, we announced that we were named a member of the Additive Alliance of Fraunhofer IAPT, a leading network for additive manufacturing (“AM”). As the first US company to be granted a membership in the Alliance, Sigma became part of the global research consortium to advance the development and implementation of AM. The membership enables us to demonstrate our PrintRite3D® technology to key players in the market of metal AM.

On February 5, 2019, we announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/276,452, “Optical Manufacturing Process Sensing and Status Indication System.” The patent application covers a system of sensors configured to measure optical emissions generated by a scanning heat source during an additive manufacturing (AM) process and to analyze the data collected.

On January 17, 2019, we announced we were awarded a Test and Evaluation Program contract with a leading global materials and service provider in AM. The program is designed to demonstrate the value of Sigma’s PrintRite3D® product capabilities and performance and to validate and quantify the repeatability and variability of AM production processes. So far we have had delays, diversions, and logistical alterations typical of many newly launched programs, yet importantly, there have been no longernegative performance issues in compliancethe RTE test results. The prototype RTE installation was with Materialise in 2018 and culminated in the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Marketproject announced in June 2019 to maintain stockholders’ equity of at least $2,500,000. In this Quarterly Report, the Company reported stockholders’ equity of $4,127,814 as of June 30, 2018, which is above the minimum stockholders’ equity required for continued listing. Accordingly, asintegrate Sigma’s technology with Materialise’s MCP control system. As of the date of this Quarterly Report, of our two most advanced RTEs in process, one states an expectation to add a second PrintRite3D® installation, and the Company believes that it has regained compliance with Nasdaq Listing Rule 5550(b)(1).other expects to enter the phase two evaluation (multiple machines of differing OEM brands) over the next 60-120 days.

 

On May 14, 2018, we announced the inaugural hire of our European customer salesThe size and support team.

During April 23-26, 2018 the Company participated in The Rapid 2018 Conference in Fort Worth, Texas, at which the Company exhibited its PrintRite3D® In-Process Quality Assurance (IPQA®) software applications.

During April 8-12, 2018, the Company participated in The Additive Manufacturing Users Group (AMUG) Conference and Exhibition in St. Louis, Missouri. Mark Cola, our President and Chief Technology Officer, participated as a panel member in the In-Situ Monitoring Panel discussion, which focused on the time and cost associated with validationquality of the manufacturing process for aerospace quality components.

On April 6, 2018,demanding high technology ‘brand name’ companies currently participating in, along with those teed-up to enter the Company closed a private placementRTE program, appears to confirm that the program is Sigma’s most auspicious highway to success and material revenue driving into 2020 and beyond. The Airbus RTE announcement on July 30, 2019 followed by our OEM double-RTE announcement on August 13, 2019 demonstrates that the market’s uptake of preferred stock and warrants resulting in net proceeds of approximately $877,500, after deducting commissions and other offering expenses payable by the Company. All shares of preferred stock that were issued in the offering were converted into an aggregate of 1,000,000 shares of common stock during the second quarter of 2018.this program initiative is accelerating.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the accompanying consolidated financial statements and related notes. These estimates and assumptions have a significant impact on our consolidated financial statements. Actual results could differ materially from those estimates. Critical accounting policies are those that require the most subjective and complex judgments, often employing the use of estimates about the effect of matters that are inherently uncertain. Our significant accounting policies are disclosed in Note 1 to the Financial Statements included in this Quarterly Report on Form 10-Q. However, we do not believe that there are any alternative methods of accounting for our operations that would have a material effect on our financial statements.

 

Results of Operations

 

Three Months Ended June 30, 2019 and June 30, 2018

We expect to generate revenue primarily by selling and licensing our IPQA technologies, selling technical support services, and contract manufacturing and selling specialty parts and studies to businesses that seek to improve their manufacturing production processes and production-run quality yields. Our ability to generate revenues in the future will depend on our ability to further commercialize and increase market presence of our PrintRite3D® technologies, and it will depend on ifwhether key prospective customers continue to move from AM metal prototyping to production.

Three Months Ended June 30, 2018 and 2017

In the second quarter of 2018, we recognized revenue of $98,663 compared to $290,553 during the same period of 2017. The primary contributors to the $191,890 reduction were revenue decreases of $118,737 from the DARPA and Aerojet government programs and $128,174 from new system sales. These decreases were partially offset by an increase in net other revenue in the second quarter of 2018, principally attributable to $49,031 in revenue from contract AM service sales in the second quarter of 2018 compared to no such sales in the second quarter of 2017. Our cost of revenue for the second quarter of 2018 was $68,568 as compared to $111,412 during the same period of 2017. The decrease of $42,844 is primarily due to $43,915 of system costs associated with the second quarter 2017 system sales.

Sigma’s total operating expenses for the second quarter of 2018 were $1,422,511 compared to $1,108,234 for the same period of 2017, a $314,277 increase. Our operating expenses are comprised of internal operating and sales expenses, outside service fees, research & development costs, and depreciation & amortization.

The most significant of our operating expenses is personnel costs, comprised of payroll and stock-based compensation expense. Payroll costs in the second quarter of 2018 were $426,049 compared to $346,994 for the same period in 2017. The $79,055 increase result primarily from the strategic addition of six employees since the end of the second quarter of 2017, three in the third quarter of 2017 realignment and three in the second quarter of 2018 as we continue the concentrated acceleration of technology development and expand into the European 3D manufacturing market. Stock-based compensation for the second quarter of 2018 was $423,067 compared to $166,773 for the same period in 2017. The $256,294 increase resulted primarily from the issuance of stock options to our Chief Executive Officer in the second quarter of 2018, $61,651 of additional stock options vesting expense related to the options issued to our President and Chief Technology Officer under his amended and restated employment agreement, and the amortization of an additional $72,494 in Board of Director stock compensation cost in that same 2018 period.

 

During the three months ended June 30, 2019, we recognized revenue of $33,582, as compared to $98,663 in revenue recognized during the same period in 2018, Sigma incurred researcha reduction of $65,081. $10,000 of the reduction is directly attributable to the absence of any government program work in 2019, while the remaining 55,000 of it is attributable to the 100% dedication of our printer to Internal R&D in the second quarter of 2019 as we accelerated development of the Inspect product, as well as an overall decline in AM revenue.

Our Cost of Revenue for the three months ended June 30, 2019 and 2018 was $60,625 and $68,568, respectively, a reduction of $7,943. The decrease in our gross margin is primarily attributable to the additional travel and labor costs associated with the on-site and remote collaboration involved in initiation of the Company’s Rapid Test and Evaluation programs.

13

Sigma’s total operating expenses for the three months ended June 30, 2019 were $1,569,064 as compared to $1,422,511 for the same period in 2018, an increase of $146,553.

Salary and benefits costs were $581,356 for the three months ended June 30, 2019 compared to $426,049 for the same period in 2018, an increase of $155,307. This 36% cost increase correlates to a net increase of five full-time equivalent employees between the two periods which is a 31% increase in employee count.

Stock-based compensation was $220,360 for the three months ended June 30, 2019 compared to $423,067 for the same period in 2018, a $202,707, or 48%, decrease, primarily due to 2018 second quarter vesting of options granted to our former CEO in connection with his amended employment agreement.

Research and development expenditures of $95,045$118,845 were incurred during the three months ended June 30, 2019 compared to $131,908$95,049 in the same period of 2017.2018, a 25% increase. The $36,863 decrease in these expenditures resultedincrease primarily results from a reduction in the amountpurchase of third party consulting utilized in Sigma’s Inspect 2.0 softwareupgraded PrintRite3D® components and contour hardware development between the two periods.

various pieces of specialized equipment as part of our continued acceleration of technology development.

 

Sigma’s public company costs and investor relationOutside services fees incurred in the second quarter of 2018three months ended June 30, 2019 were $103,197$218,919 compared to $131,780$177,929 incurred during the same period in 2017.2018, a 23% increase. The $28,583 decrease in the three-month comparative expenditures resultedincrease is primarily from the timing of the payment of the $38,500 annual Nasdaq registration fee between the two years.attributable to recruiting fees for senior employees.

 

DuringOffice expenses incurred during the second quarterthree months ended June 30, 2019 were $184,068 compared to $110,936 incurred during the same period in 2018, an increase of 2018, Sigma’s$73,132, or 66%. The increase is primarily due to increased travel costs of $59,936, and other miscellaneous office expenses were $110,936of $13,196.

Sigma’s net loss for the three months ended June 30, 2019 totaled $1,593,491 as compared to $64,739 in$1,388,804 for the same period of 2017.2018, a $204,687 increase. The $46,197 increasereduction in these expenditures resulted primarily from the purchase of computer hardware and software and the rental of additional office space for new employee hires in the last half of 2017 and the second quarter of 2018, and from additional travel expense related to both a more aggressive outreach to prospective EOM and service bureau clients and our expansion into the European market in the second quarter of 2018.

In the second quarter of 2018, our net other income & expense was net income of $3,612 compared to net other expense of $59,646 in the second quarter of 2017. The second quarter 2018 net income was comprised of $3,719 of interest income on the remaining note receivable balance and an exchange rate gain of $1,304 offset by $1,411 of interest expense on the remaining balance of the note payable. This compares to $12,598 of interest income on the original note receivable balance offset by $49,862 of interest expense and a $22,382 loss on disposal of computer software in the second quarter of 2017.

Sigma’s total net loss for the second quarter of 2018 was $1,388,804 as compared to $988,741 for the second quarter of 2017, a $400,063 increase with operating income contributing $463,323gross profit contributed $57,138 to the increased loss, andwhile increased other income and expense offsetting it by $63,260.

operating expenses contributed $146,553 to the increased loss.

 

Six Months Ended June 30, 20182019 and 20172018

 

During the six months ended June 30, 2018,2019, we recognized revenue of $202,078$98,032 compared to $405,076 of revenue recognized$202,078 during the same period of 2017.2018. The primary contributors to the $202,998$104,046 reduction were revenue decreases of $134,473$32,300 from the DARPAabsence of any government work, $63,000 is attributable to the 100% dedication of our printer to Internal R&D in 2019, and Aerojet government programs and $130,561the balance from an overall decline in new system sales, partially offset by increased in net other revenue in the 2018, primarily, $58,631 of contract AM service sales. revenue.

Our cost of revenue for the six months ended June 30, 20182019 was $142,363$157,180 compared to $185,946$142,363 during the same period in 2017.2018. The decreaseincrease of $43,583$14,817 is primarily due to $43,915 of systemthe additional travel and labor costs associated with the second quarter 2017 system sales.on-site and remote collaboration involved in initiation of the Company’s Rapid Test and Evaluation programs.

 

Sigma’s total operating expenses for the six months ended June 30, 20182019 were $2,599,641$3,076,162 compared to $2,114,717$2,599,641 for the same period in 2017,2018, a $484,924$476,521 increase.

 

Payroll costs for the six months ended June 30, 20182019 were $824,706$1,093,916 compared to $785,204$824,706 for the same period in 2017.2018. The $39,502$269,210 increases result primarily from the earlier mentioned addition of sixfive employees since the end of the second quarter of 2017, partially offset by a $50,000 bonus payment in 2017 to our Vice President of Business Development in connection with the satisfaction of performance milestones.2018. Stock-based compensation for the six months ended June 30, 20182019 was $584,589$474,566 compared to $306,405$584,589 for the same period in 2017. This $278,184 increase resulted2018, a $110,023 decrease, primarily fromdue to the previously detailedvesting of options vesting and shares amortization increases that occurredgranted to our former CEO in the second quarter ofconnection with his amended employment agreement in 2018.

 

During the six months ended June 30, 2018,2019, Sigma incurred research and development expenditures of $217,022$264,177 compared to $186,413$217,022 in the same period of 2017.2018. The $30,609$47,155 increase in these expenditures during the first six months of 20182019 resulted primarily from the purchase of multiple upgraded servers and various pieces of specialized equipment as part of our continued concentrated acceleration of technology development.development, as well as $35,333 of consulting fees paid in connection with the development of Version 5.0 of our PrintRite3D®platform.

Sigma’s public company and investor relation fees incurred in the six months ended June 30, 20182019 were $283,596,$315,107, compared to $243,913$283,596 during the same period in 2017.2018. The $39,683$31,511 increase in the six-month comparative expenditures results primarily from the $122,263an increase in stock and cash compensation paid to non-employee board members in 2018advertising expenses of $64,600, partially offset by a reductiondecrease in shareholder services expenses of $82,573$37,100.

Outside services fees incurred in amortization expense relatedthe six months ended June 30, 2019 were $403,489, compared to stock compensation paid$316,352 incurred during the same period in 2018, a 28% increase. Consulting fees increased by $67,552 due to officersthe addition of the company in 2017.an application engineer consultant, and recruiting fees increased by $19,428.

14

 

During the six months ended June 30, 2018,2019, Sigma’s Office Expensesoffice expenses were $206,042$350,178 compared to $148,944$206,042 in the same period of 2017.2018. The $57,098 increases$144,136 increase in these expenditures primarily resulted primarily from $27,787 in additional 2018 hardware, software, supplies and office space costs for new employees, and from $28,296 additional 2018 travel expense related to both a more aggressive outreach to prospective OEM, service bureau and end user customers and our expansion into the European market.

 

In the six months ended June 30, 2018,2019, our net other income & expense was anet income of $57,707, as compared to net expense of $19,754 as compared toduring the same period in 2018. The six-month 2019 net other income is primarily comprised of $80,214$52,000 in New Mexico state job incentive credits received. The net other expense for the same periods of 2017. The six-monthperiod in 2018 net expense wasis primarily comprised ofdue to a $36,733 write-off of patent and patent application costsaccounting software, partially offset by interest income of $17,086 on the then outstanding notes receivable. The 2017 net positive contribution for the six-month period is comprised of $152,068 in New Mexico state job incentive credits received and a $93,206 positive revaluation of derivatives offset by $56,441 of debt amortization expense, $99,178 of interest expense on the $1,000,000 notes originated in October of 2016 and a $22,2382 write-off of computer software.

 

Sigma’s net loss for the six months ended June 30, 20182019 totaled $2,559,680$3,077,603 as compared to $1,815,373$2,559,680 for the same period in 2018, a $517,923 increase. Contributing to this increase was an increase in our operating loss of 2017,$595,384, consisting of a $744,307decrease in gross profit of $118,863, together with an increase within operating income contributing $644,338 andexpenses of $476,521. This was partially offset by an increase in other income and expense contributing $99,969.of $77,461.

 

We financed our operations during the three and six months ended June 30, 20182019 and 20172018 primarily from revenue generated from PrintRite3D® system sales and engineering consulting services we provided to third parties during these periods and through sales of our common and preferred stock and, in 2017, through the issuance of debt securities.stock. We expect that our revenue will increase in future periods as we seek to further commercialize and expand our market presence for our PrintRite3D®-related technologies and obtain new contract manufacturing orders in connection with our EOS M290.

 

Liquidity and Capital Resources

 

As of June 30, 2018,2019, we had $3,519,637$696,390 in cash and had a working capital surplus of $3,320,502,$685,409, as compared with $1,515,674$1,279,782 in cash and a working capital surplus of $2,273,801$1,052,017 as of December 31, 2017.2018.

 

Our major sources of funding have been proceeds from public and private offerings of our equity securities (both common stock and preferred stock), and from warrant exercises. On April 6, 2018,

In March 2019, the Company closed a public offering of equity securities in which it issued 1,400,800 shares of common stock and warrants to purchase a total of 420,240 shares of common stock resulting in net proceeds of approximately $1,679,330, after deducting placement agent commissions and other offering expenses payable by the Company.

In May 2019, the Company closed a private placement of equity securities in which it issued 400,000 shares of common stock and warrants to purchase a total of 220,000 shares of common stock resulting in net proceeds of approximately $920,000,$515,000, after deducting placement agent commissions and other offering expenses payable by the Company. On June 26, 2018,

In August 2019, the Company closed a public offering of equity securities in which it issued 2,875,000 shares of common stock resulting in net proceeds of approximately $2,139,000,$1,971,000, after deducting placement agent commissions and other offering expenses payable by the Company. The principal balance in the amount of $50,000 and any accrued and unpaid interest on the convertible promissory note that is payable by us is due in October 18, 2018.

 

During the remainder of 2018,2019, we expect to further ramp upsustain our operations and our commercialization and marketing efforts which willwithout a material increase the amount of cash we will use in our operations.cash burn rate. We expect that our continued developmentenhancements of our IPQA®-enabled PrintRite3D® technology that were developed substantially in fiscal 2018 and 2019 and brought to market will enable us to further commercialize this technology for the AM metal market in 2018.2019 and beyond. However, until commercialization of our full suite of PrintRite3D® technologies, we plan to continue funding our development activities and operating expenses by licensing our PrintRite3D® systems and supporting field services, as applicable, and providing PrintRite3D®-enabled engineering consulting services concerning our areas of expertise (materials and manufacturing quality assurance and process control technologies) and contract manufacturing for metal AM, and through the use of proceeds from sales of our securities.

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities during the six months ended June 30, 20182019 increased to $1,472,519$2,737,650 from $1,291,060$1,472,519 during the same period in 2017, an increase of $181,459. Sigma’s higher2018, a $1,265,131 increase. Increased net loss in the six months ended June 30, 2018 contributed $429,006 to$517,923 toward this increase while more conservative managementuse of cash, increased inventory purchases contributed $377,440 as a result of our finished goods ramp program, and payables offset $87,686a net decrease of accounts payable and $162,065 of that increased use, respectively.accrued expenses contributed $164,370.

 

Net Cash Used/Provided by Investing Activities

 

Net cash providedused by investing activities during the six months ended June 30, 20182019 was $530,082,$115,920, which compares to $530,082 of cash used inprovided by investing activities during the same period of 2017 totaling $795,468. The $1,325,550 positive swing2018, a decrease of $646,002. This is primarily attributable primarily to the March 2018 receipt of payment in full of thea then outstanding $500,000 loan made to Morf3D in March of 2017, and receipt of $150,000 in partial payment of the $250,000 loan made to Jaguar Precision Machines in May of 2017.receivable.

15

Net Cash Used/Provided by Financing Activities

 

Cash provided by financing activities during the six months ended June 30, 20182019 decreased to $2,946,400$2,270,178 from $5,072,636$2,946,400 during the same period in 2017,2018 due to the receipt of a total of $3,390,100 oflower proceeds less $443,700 of offering costs from our April 2018public and private placement and June 2018 public offering compared to the receipt of $5,823,300 of proceeds less $750,664 of offering costs, from our February 2017 public offering.securities offerings in 2019.

 

The Company anticipates less losscontinued losses in 2018, due to2019, with any expected increased revenues offset by increased salaries and related expenses in connection with additional employees and potential acquisitions (although there are no agreements with respect to the acquisition by the Company of any third party, and there can be no assurance that any agreements will be entered into or, if entered into, that any acquisition or other transaction will be consummated).employees.

 

We have no credit lines as of August 13, 2018,14, 2019, nor have we ever had a credit line since our inception.

 

Based on the funds we have as of August 13, 2018,14, 2019, and the proceeds we expect to receive underfrom rapid test and evaluation engagements for our PrintRite3D®-enabled engineering consulting agreements, from selling or licensing ourupdated PrintRite3D® systemshardware and software andtechnology, sales of contract AM manufacturing for metal AM parts, possible sales of our securities and from the repayment of loans made by Sigma, we believe that we will have sufficient funds to pay our administrative and other operating expenses through at least the first quarter of 2019. Our ability to continue to fund our liquidity and working capital needs will be dependent upon the success of and revenues from existing and future PrintRite3D®-enabled engineering consulting-proof of concept contracts, follow-on contracts resulting from successful proof of concept engagements, possible strategic partnerships, contract manufacturing orders in connection with our EOS M290, and perhapspossibly by obtaining additional capital from the sale of additional securities or by borrowing funds from lenders to fulfill our business plans. If we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. There is no assurance that we will be successful in obtaining additional funding. If we require and fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations.

 

We have no off-balance sheet arrangements as defined in Item 303(a) of Regulation S-K.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of disclosure controls and procedures.procedures and changes in internal controls over financial reporting.

Rule 13a-15(e) under the Exchange Act defines the term “disclosure controls and procedures” as those controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our management, with the participation of our Chief Executive Officer, and our Principal Financial and Accounting Officer, as of the end of the period covered by this quarterly report, our management concluded that our disclosure controls and procedures are effective at a reasonable assurance level in ensuring that information required to be disclosed by us in our reports is recorded, processed, summarized and reported within the required time periods.

Changes in internal controls over financial reporting. In addition, no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) occurred during the three months ended June 30, 20182019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

16

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

Not applicable.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On April 6, 2018,May 7, 2019, we issued to twoan accredited investors Series B Preferred Stock that was convertible into up to an aggregate of 1,000,000investor 400,000 shares of our common stock and we issued warrants to purchase up to 890,000a total of 200,000 shares of our common stock. We also Sigma issued to Dawson James Securities, Inc., our placement agent in the foregoing private placement, warrants to purchase up to 140,00020,000 shares of common stock, as compensation. Between May 29, 2018 and June 1, 2018, we issued a total of 1,000,000 shares of common stock upon conversion of the foregoing Series B Preferred Stock. The foregoing securities were issued in reliance upon an exemption from the registration requirements pursuant to Section 4(2) of the Securities Act.

On June 26, 2018, we issued to Dawson James Securities, Inc., our placement agent in the June 2018 public offering, a Unit Purchase Option to acquire up to 191,200 Units, at an exercise price of $1.25 per Unit, consisting of 191,200 shares of common stock and warrants to purchase up to 57,360 shares of common stock as compensation. The Unit Purchase Option was issued in reliance upon an exemption from the registration requirements pursuant to Section 4(2) of the Securities Act.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

Not applicable.None.

ITEM 6. EXHIBITS.

 

1.1

Placement AgencyUnderwriting Agreement, dated as of June 22, 2018, betweenJuly 30, 2019, by and among Sigma Labs, Inc. and Dawson James Securities, Inc..(filedAegis Capital Corp. acting as the representative of the several underwriters named on Schedule I thereto (filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed June 26, 2018,August 1, 2019, and incorporated herein by reference).

3.1Certificate of Designation of Rights, Preference and Privileges of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed April 6, 2018, and incorporated herein by reference).
3.2Certificate of Designation of Rights, Preference and Privileges of Series C Convertible Preferred Stock of Sigma Labs, Inc. (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 26, 2018, and incorporated herein by reference).

  
4.1Form of Common Stock Purchase Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed April 6, 2018, and incorporated herein by reference).
4.2Form of Placement Agent Warrants (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed April 6, 2018, and incorporated herein by reference).
4.3Form of Common Stock Purchase Warrant.(filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed June 26, 2018,May 8, 2019, and incorporated herein by reference).
  
4.44.2

Form of Series C Convertible Preferred Stock CertificatePlacement Agent Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed June 26, 2018,May 8, 2019, and incorporated herein by reference).

  
4.5

Form of Unit Purchase Option.(filed as Exhibit 4.3 to the Company’s Current Report on Form 8-K filed June 26, 2018, and incorporated herein by reference).

10.1Securities Purchase Agreement, dated as of April 6, 2018,May 7, 2019, between Sigma Labs, Inc.the Company and the Purchasers thereunderPurchaser (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 6, 2018May 8, 2019, and incorporated herein by reference).
10.2Employment letter agreement, effective as of July 1, 2019, between the Company and Frank D. Orzechowski.* **
10.32013 Equity Incentive Plan, as amended, of Sigma Labs, Inc. (previously filed by the Company as Annex A to the Company’s Definitive Proxy Statement on Schedule 14A filed on June 18, 2019, and incorporated herein by reference).*
  
31.1Rule 13a-14(a) Certification of Principal Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
  
31.2Rule 13a-14(a) Certification of Principal Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
  
32.1Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***
  
101.INS++101.INSXBRL Instance Document.**
101.SCH++101.SCHXBRL Schema Document.**
101.CAL++101.CALXBRL Calculation Linkbase Document.**
101.DEF++101.DEFXBRL Definition Linkbase Document.**
101.LAB++101.LABXBRL Labels Linkbase Document.**
101.PRE++101.PREXBRL Presentation Linkbase Document.**

 

* Indicates a management contract or compensatory plan or arrangement.

** Filed herewith.

++ Pursuant to applicable securities laws*** Furnished herewith and regulations, the Registrant is deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and is not subject to liability under any anti-fraud provisions of the federal securities laws as long as the Registrant has made a good faith attempt to comply with the submission requirements and promptly amends the interactive data files after becoming aware that the interactive data files fails to comply with the submission requirements. These interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.amended.

17

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 SIGMA LABS, INC.
   
August 14, 20182019By:/s/ John Rice
  John Rice
  

Chairman of the Board, President and Chief Executive Officer (Principal Executive Officer)

   
August 14, 20182019By:/s/ Nannette ToupsFrank Orzechowski
  Nannette ToupsFrank Orzechowski
  Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

18